Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.72 |
| ▸ | DRD4 | P21917 | 9/20 | 0.72 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.67 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.67 |
| ▸ | HTR2A | P28223 | 4/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.67 |
| ▸ | CCR2 | P41597 | 4/20 | 0.66 |
| ▸ | MC4R | P32245 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6708023 | 0.85 | MCHR1 (0.71) | DRD2DRD4MCHR1CHRM1HTR2A | |
| SCHEMBL8706523 | 0.84 | DRD2 (1.00) | DRD2DRD4HTR2ACCR2 | |
| SCHEMBL22716940 | 0.84 | DRD2 (0.66) | DRD2DRD4CCR2 | |
| SCHEMBL6706046 | 0.82 | MCHR1 (0.67) | DRD2DRD4MCHR1CHRM1HTR2A | |
| SCHEMBL3875301 | 0.81 | MCHR1 (1.00) | MCHR1CHRM1HTR2ACYP2D6 | |
| SCHEMBL3879136 | 0.81 | MCHR1 (1.00) | MCHR1CHRM1HTR2ACYP2D6 | |
| SCHEMBL3870667 | 0.80 | MCHR1 (1.00) | MCHR1CHRM1HTR2ACYP2D6 | |
| SCHEMBL8707354 | 0.78 | DRD2 (1.00) | DRD2DRD4MCHR1HTR2ACYP2D6 | |
| SCHEMBL8706290 | 0.78 | DRD2 (1.00) | DRD2DRD4MCHR1HTR2ACYP2D6 | |
| SCHEMBL3870972 | 0.78 | MCHR1 (0.80) | MCHR1CHRM1HTR2ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-02 | — | — | US | claimed |
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | MCHR2, MCHR1, NPY1R | DRD2 286/4885DRD4 416/4885MCHR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.